Adial Pharmaceuticals, Inc.
ADIL
$0.2454
$0.00642.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.52M | 1.21M | 1.18M | 1.27M | 1.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.27M | 1.94M | 2.21M | 2.29M | 1.85M |
| Operating Income | -2.27M | -1.94M | -2.21M | -2.29M | -1.85M |
| Income Before Tax | -2.23M | -2.07M | -2.19M | -2.46M | -6.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.23M | -2.07M | -2.19M | -2.46M | -6.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.23M | -2.07M | -2.19M | -2.46M | -6.48M |
| EBIT | -2.27M | -1.94M | -2.21M | -2.29M | -1.85M |
| EBITDA | -2.27M | -1.94M | -2.21M | -2.29M | -1.84M |
| EPS Basic | -0.34 | -0.32 | -0.38 | -0.59 | -2.19 |
| Normalized Basic EPS | -0.21 | -0.68 | -0.23 | -0.37 | -1.37 |
| EPS Diluted | -0.34 | -0.32 | -0.38 | -0.59 | -2.19 |
| Normalized Diluted EPS | -0.21 | -0.68 | -0.23 | -0.37 | -1.37 |
| Average Basic Shares Outstanding | 6.54M | 6.42M | 5.84M | 4.18M | 2.95M |
| Average Diluted Shares Outstanding | 6.54M | 6.42M | 5.84M | 4.18M | 2.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |